Related references
Note: Only part of the references are listed.NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes
Anju Singh et al.
CLINICAL CANCER RESEARCH (2021)
Breakthrough in targeted therapy for non -small cell lung cancer
Zhencong Ye et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
Evgeny N. Imyanitov et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Functional assessment of somatic STK11 variants identified in primary human non-small cell lung cancers
Liam L. Donnelly et al.
CARCINOGENESIS (2021)
The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
Baharia Mograbi et al.
DIAGNOSTICS (2021)
Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer
Moom R. Roosan et al.
CHEST (2021)
STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications
Nithya Krishnamurthy et al.
EUROPEAN JOURNAL OF CANCER (2021)
Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review)
Liu Yang et al.
ONCOLOGY REPORTS (2021)
piRNAs: biogenesis and their potential roles in cancer
Binghong Guo et al.
CANCER AND METASTASIS REVIEWS (2020)
p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival
Longfei Deng et al.
NATURE COMMUNICATIONS (2020)
STK11 mutation status is associated with decreased survival in meningiomas
Corey M. Gill et al.
NEUROLOGICAL SCIENCES (2020)
The emerging roles of artificial intelligence in cancer drug development and precision therapy
Guosheng Liang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D. Ross Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
How to overcome the side effects of tumor immunotherapy
Shang Li et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
Norah J. Shire et al.
PLOS ONE (2020)
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti et al.
CANCERS (2020)
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
Wolfgang M. Brueckl et al.
BMC CANCER (2020)
Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer
Corrin A. Wohlhieter et al.
CELL REPORTS (2020)
How to select the best upfront therapy for metastatic disease. Focus on ALK-rearranged non-small cell lung cancer (NSCLC)
Bing Xia et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
Valerio Gristina et al.
PHARMACEUTICALS (2020)
Longitudinal health utilities, symptoms and toxicities in patients with ALK-rearranged lung cancer treated with tyrosine kinase inhibitors: a prospective real-world assessment
B. C. Tse et al.
CURRENT ONCOLOGY (2020)
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
D. Ross Camidge et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma
Ana Galan-Cobo et al.
CANCER RESEARCH (2019)
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Xiaotian Kong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
LKB1/AMPK Pathway and Drug Response in Cancer: A Therapeutic Perspective
Francesco Ciccarese et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2019)
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
R. S. Herbst et al.
ANNALS OF ONCOLOGY (2019)
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer
Maurice Pérol et al.
LUNG CANCER (2019)
Circular RNAs: The star molecules in cancer
Jianhong Liu et al.
MOLECULAR ASPECTS OF MEDICINE (2019)
Targeted drugs ramp up cancer mutability
Marco Gerlinger
SCIENCE (2019)
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J. Solomon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
Ferdinandos Skoulidis et al.
CANCER DISCOVERY (2018)
ALK-rearrangement in non-small-cell lung cancer (NSCLC)
Xue Du et al.
THORACIC CANCER (2018)
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio et al.
CANCER RESEARCH AND TREATMENT (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Geeta Geeta Sharma et al.
CANCERS (2018)
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer
Yifan Wang et al.
CLINICAL CANCER RESEARCH (2018)
Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
Michael T. Werner et al.
BLOOD (2017)
Biological therapies in nonsmall cell lung cancer
Jon Zugazagoitia et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma
Ildiko Krencz et al.
HUMAN PATHOLOGY (2017)
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer
Kyoung Ho Pyo et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
Francesco Facchinetti et al.
LUNG CANCER (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
LKB1 promotes radioresistance in esophageal cancer cells exposed to radiation, by suppression of apoptosis and activation of autophagy via the AMPK pathway
Qing He et al.
MOLECULAR MEDICINE REPORTS (2017)
LKB1 pro-oncogenic activity triggers cell survival in circulating tumor cells
Elisabeth Katharina Trapp et al.
MOLECULAR ONCOLOGY (2017)
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Drug resistance in ALK-positiveNon-small cell lungcancer patients
Mengjia Qian et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet J. Jordan et al.
CANCER DISCOVERY (2017)
LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway
Weiming Zhang et al.
ONCOTARGET (2017)
Understanding and targeting resistance mechanisms in NSCLC
Julia Rotow et al.
NATURE REVIEWS CANCER (2017)
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Fiona Blackhall et al.
ESMO OPEN (2017)
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant
Christine A. Parachoniak et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
M. B. Schabath et al.
ONCOGENE (2016)
The role of the ALK receptor in cancer biology
B. Hallberg et al.
ANNALS OF ONCOLOGY (2016)
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment
Shohei Koyama et al.
CANCER RESEARCH (2016)
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)
Hideko Isozaki et al.
CLINICAL LUNG CANCER (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Lucio Crino et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
AMPK Facilitates Nuclear Accumulation of Nrf2 by Phosphorylating at Serine 550
Min Sung Joo et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Re-Evaluating Progression in an Era of Progress: A Review of First- and Second-Line Treatment Options in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Emily H. Castellanos et al.
ONCOLOGIST (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Alectinib for ALK-positive non-small-cell lung cancer
Antonio Rossi
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)
New treatment options for ALK plus advanced non-small-cell lung cancer: critical appraisal of ceritinib
Sacha I. Rothschild
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells
Yuan-Hu Yao et al.
CHINESE JOURNAL OF CANCER (2016)
Targeting LKB1 in cancer - exposing and exploiting vulnerabilities
M. Momcilovic et al.
BRITISH JOURNAL OF CANCER (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2015)
Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer
Bojiang Chen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma
Jian-Yu Yang et al.
SCIENTIFIC REPORTS (2015)
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
Gouji Toyokawa et al.
ONCOLOGY RESEARCH AND TREATMENT (2015)
A novel LKB1 isoform enhances AMPK metabolic activity and displays oncogenic properties
R. Dahmani et al.
ONCOGENE (2015)
Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer
Pradeep S. Tanwar et al.
CARCINOGENESIS (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Loss of LKB1 disrupts breast epithelial cell polarity and promotes breast cancer metastasis and invasion
Juan Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas
Rong Fang et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib
Gouji Toyokawa et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system
Danilo Maddalo et al.
NATURE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models
Grit S. Herter-Sprie et al.
NATURE COMMUNICATIONS (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
David B. Shackelford et al.
CANCER CELL (2013)
AMPK: A Contextual Oncogene or Tumor Suppressor?
Jiyong Liang et al.
CANCER RESEARCH (2013)
AMP Is a True Physiological Regulator of AMP-Activated Protein Kinase by Both Allosteric Activation and Enhancing Net Phosphorylation
Graeme J. Gowans et al.
CELL METABOLISM (2013)
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Monica Ceccon et al.
MOLECULAR CANCER RESEARCH (2013)
Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers
Su Man Lee et al.
LUNG CANCER (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
LKB1/STK11 Inactivation Leads to Expansion of a Prometastatic Tumor Subpopulation in Melanoma
Wenjin Liu et al.
CANCER CELL (2012)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Sang-Min Jeon et al.
NATURE (2012)
Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma
Andres Morales La Madrid et al.
TARGETED ONCOLOGY (2012)
A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Takaaki Sasaki et al.
CANCER RESEARCH (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
Targeting Anaplastic Lymphoma Kinase in Lung Cancer
Alice T. Shaw et al.
CLINICAL CANCER RESEARCH (2011)
Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer
R. K. Gill et al.
ONCOGENE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Zhao Chen et al.
CANCER RESEARCH (2010)
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer
Akihiko Yoshizawa et al.
CLINICAL CANCER RESEARCH (2010)
Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells
Badal C. Roy et al.
LUNG CANCER (2010)
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
C. L. Mahoney et al.
BRITISH JOURNAL OF CANCER (2009)
Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2009)
Somatic LKB1 Mutations Promote Cervical Cancer Progression
Shana N. Wingo et al.
PLOS ONE (2009)
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
David B. Shackelford et al.
NATURE REVIEWS CANCER (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
J. P. Koivunen et al.
BRITISH JOURNAL OF CANCER (2008)
Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts
Kengo Takeuchi et al.
CLINICAL CANCER RESEARCH (2008)
Pancreatic Lkb1 deletion leads to acinar polarity defects and cystic neoplasms
Aram F. Hezel et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2008)
A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome
M. Sanchez-Cespedes
ONCOGENE (2007)
Prevalence and specificity of LKB1 genetic alterations in lung cancers
S. Matsumoto et al.
ONCOGENE (2007)
LKB1 modulates lung cancer differentiation and metastasis
Hongbin Ji et al.
NATURE (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity
C Forcet et al.
HUMAN MOLECULAR GENETICS (2005)
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
RJ Shaw et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate for proteasomal degradation of Nrf2
A Kobayashi et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
LKB1 tumor suppressor protein: PARtaker in cell polarity
AF Baas et al.
TRENDS IN CELL BIOLOGY (2004)
Share Paper
